申请人:Aventis Pharma limited
公开号:US20040198737A1
公开(公告)日:2004-10-07
Chemical compositions containing physiologically active compounds of general formula (I):
1
wherein R
1
is aryl or heteroaryl; R
2
represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z
1
R
8
, —C(═O)—NY
3
Y
4
, —CO
2
R
8
, —NY
3
Y
4
, —N(R
6
)—C(═O)—R
7
, —N(R
6
)—C(═O)—NY
3
Y
4
, —N(R
6
)—C(═O)—OR
7
, —N(R
6
)—SO
2
—R
7
, —N(R
6
)—SO
2
—NY
3
Y
4
and one or more halogen atoms; R
3
represents hydrogen, a cyano, halo, heteroaryl, lower alkyl, —C(═O)—OR
5
or —C(═O)—NY
3
Y; and X
1
represents N, CH, C-halo, C—CN, C—R
7
, C—NY
3
Y
4
, C—OH, C-Z
2
R
7
, C—C(═O)—OR
5
, C—C(═O)—NY
3
Y
4
, C—N(R
8
)—C(═O)—R
7
, C—SO
2
—NY
3
Y
4
, C—N(R
8
)—SO
2
—R
7
, C-alkenyl, C-alkynyl or C—NO
2
; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I).
Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.
化学成分包含通式(I)的生理活性化合物:1其中R1为芳基或杂芳基;R2表示氢,酰基,
氰基,卤素,较低烯基或较低烷基,可选择由
氰基,杂芳基,杂环烷基,-Z1R8,-C(═O)-NY3Y4,-CO2R8,-NY3Y4,-N(R6)-C(═O)-R7,-N(R6)-C(═O)-NY3Y4,-N(R6)-C(═O)-OR7,-N(R6)-SO2-R7,-N(R6)-SO2-NY3Y4和一个或多个卤素原子取代的基团;R3表示氢,
氰基,卤素,杂芳基,较低烷基,-C(═O)-OR5或-C(═O)-NY3Y;X1表示N,CH,C-卤素,C-CN,C-R7,C-NY3Y4,C-OH,C-Z2R7,C-C(═O)-OR5,C-C(═O)-NY3Y4,C-N(R8)-C(═O)-R7,C-SO2-NY3Y4,C-N(R8)-SO2-R7,C-烯基,C-炔基或C-
NO2;以及它们的前药和这些化合物及其前药的药学上可接受的盐和溶剂,以及在公式(I)范围内的新化合物。这些化合物和组合物具有有价值的药物特性,特别是抑制蛋白激酶的能力。